Microdialysis
of the ventral tegmental area in conscious rats was used to evaluate the influence of opioids and GABA agonists on extracellular levels of GABA and somatodendritically released dopamine.
The administration of morphine through the dialysis probe elicited significant, dose-dependent increases in the levels of extracellular dopamine and significantly reduced the extracellular concentration of GABA. In contrast, a dose-dependent decrease in somatodendritic extracellular dopamine was produced following the administration of the GABA,agonist baclofen. The increase in dopamine levels elicited by morphine (100 AM) was completely blocked by either baclofen (100 HM) coadministration or peripheral injection of naloxone (2 mg/kg, i.p.). Application of the GABA,agonist muscimol produced a significant increase in both extracellular levels of dopamine and locomotor activity. The present results, together with other electrophysiological, neurochemical, and behavioral data, support a hypothesis that stimulation of p-opioid or GABA, receptors inhibits the activity of GABAergic afferents to dopamine neurons, thereby removing tonic inhibitory regulation, whereas stimulation of GABA, receptors directly inhibits dopamine neurons.
The motor-stimulant effects of morphine and enkephalin analogs have been amply demonstrated following either peripheral (Judson and Goldstein, 1978; Veith et al., 1978; Kalivas and Duffy, 1987) or central (Joyce and Iversen, 1979; Kalivas et al., 1983; Vezina et al., 1987; Calenco-Choukroun et al., 199 1; Shippenberg, in press) administration in rodents. A variety of evidence suggests that opioid-induced hyperactivity may be mediated, at least partially, by an increase in dopaminergic activity. For example, injection of morphine or enkephalin analogs onto the A10 dopamine cell bodies in the ventral tegmental area (VTA) elicits an increase in spontaneous locomotor activity (Broekkamp et al., 1979; Joyce and Iversen, 1979; Kelley et al., 1980; Kalivas et al., 1983; Kalivas and D&y, 1990; Calenco-Chou-kroun et al., 199 1) and dopamine release and metabolism in a number of mesocorticolimbic dopamine terminal fields (Kalivas et al., 1983; Latimer et al., 1987; Cador et al., 1989; Kalivas and Duffy, 1990) , similar to the increase in metabolism seen following peripheral morphine (Moleman and Bruinvels, 1976; Westerink and Korf, 1976; Wood et al., 1980; Kalivas and Duffy, 1987) . Also, opioid-induced locomotor activity can be blocked by dopamine antagonists (Kelly et al., 1980; Iwamoto, 198 1; Kalivas et al., 1983) . In addition to stimulating dopaminedependent locomotion in the VTA, rats will self administer morphine directly into the VTA (Bozarth and Wise, 198 la) , and the microinjection of enkephalin into the VTA will produce conditioned place preference (Phillips et al., 1983) . The fact that these behaviors require an intact dopamine system suggests that at least some of the rewarding effects of opioids in the VTA result from stimulation of the ascending mesocorticolimbic dopamine system (Bozarth and Wise, 198 1 b; Phillips et al., 1983; Fibiger and Phillips, 1986) .
Electrophysiological studies indicate that opioids activate dopamine neurons indirectly (Gysling and Wang, 1983; Matthews and German, 1984; Lacey et al., 1989) possibly via inhibition of a tonic GABAergic input (Kelley et al., 1980; Johnson and North, 1992a) . In addition to p-opioid modulation of the GABAergic input, it has been suggested that inhibition of GABA release by the activation of GABA, receptors results in the stimulation of dopamine neurons, again via disinhibition (Grace and Bunney, 1979; Waszczak and Walters, 1980; . Whereas GABA, receptor agonists usually stimulate dopamine neurons in vivo, GABA, receptor agonists have been reported to produce inhibition (Olpe et al., 1977; Bunney, 1979, 1980; Waszczak and Walters, 1980) . In contrast, in vitro electrophysiological experiments reveal that the stimulation ofeither GABA, and GABA, receptors hyperpolarizes dopamine cells (Pinnock, 1984; Lacey et al., 1988; Seabrook et al., 1990; Sugita et al., 1992) .
The present study used in vivo microdialysis in the VTA of conscious rats to evaluate further the effects of opioids and GABA on somatodendritic dopamine release and extracellular levels of GABA. Previous studies have demonstrated that the extracellular levels of dopamine measured by microdialysis in the VTA and substantia nigra are calcium dependent and partially reduced by blocking voltage-dependent sodium channels and stimulating D2 autoreceptors (Kalivas and Dully, 1991; Robertson et al., 199 Pellegrino et al., 1979) . The guide cannulae were angled at 6" in order to avoid penetration of the midsaggital sinus or cerebral aqueduct and secured to the skull with three stainless steel screws and cranioplastic cement. The guide cannulae were kept patent with 25 gauge stainless steel obturators (Small Parts). Dialysis experiments began following a mininum 7 d postoperative recovery period during which rats were handled for approximately 5 min/d.
Intracranial dialysis. The dialysis probes were constructed as described by Robinson and Whishaw (1988) . Dialysis tubing extended 2.5 mm beyond the tip ofthe probe. The probe was inserted into a connector that allowed control of the depth of penetration and fixation onto the chronically implanted guide cannula (for details, see . The connector was attached to a liquid swivel that was located on a balance beam to minimize discomfort to the rat. The night before an experiment, a dialysis probe was inserted into the guide cannula and secured. A second dialysis experiment was performed in each rat on the contralateral side following a minimum 3 d intertrial interval. Dialysis buffer (5 mM KCl, 120 mM NaCl, 1.8 mM CaCl,, 1.2 mM MgCl,, plus 0.2 mM phosphate-buffered saline to give pH 7.4 and final Na+ concentration of 120.7 mM) flowed through the probe (2.13 rllmin) for 2-4 hr prior to the collection of the first sample. Following the collection of three or four 20 min baseline samples, the syringe containing buffer was switched with one containing buffer plus the test drug. Syringes containing ascending concentrations of the test drug were switched at 80 min intervals, and samples of dialysate were collected during this time at 20 min intervals. In those experiments where either a single concentration of drug or a mixture of two drugs was used, the test drug(s) was applied or "pulsed" through the probe (following the collection of three or four predrug baseline dialysate samples) for a period of 20 or 80 min. The syringe containing buffer plus drug(s) was then switched with a syringe containing dialysis buffer alone. Samples were then collected every 20 min for 120-180 min. The drugs that were tested included morphine (l-l 000 PM; Sigma Chemical, St. Louis, MO), baclofen (l-1000 PM; Sigma), and muscimol (l-1000 PM; Sigma). Naloxone HCl (2.0 mgkg, i.p.; Endo Laboratories, Garden City, NY) was dissolved in saline.
Determination of dopamine and morphine. Dialysis samples were collected into 20 ~1 of mobile phase (0.1 M citric acid, 75 mM Na,HPO,, 0.6-1.0 mM heptane sulfonic acid, 0.1 mM EDTA, 13% methanol, v/v, pH 3.8-4.2) containing 2.0 pmol of dihydroxybenzylamine as the internal standard. The concentration of dopamine within the sample was determined using HPLC-EC. Separation of biogenic amines was achieved with a reversed-phase column (C-18, 25 cm; Bioanalytical Systems, Indianapolis, IN), and detection was performed with a coulometric electrochemical system (ESA, Inc., Bedford, MA) consisting of three electrodes (guard electrode, +0.4 V; preoxidation electrode, +0.35 V, working electrode, -0.20 V). The entire sample was injected, and standard curves ranging from 0.01 to 10 pmol were used to quantify dopamine concentration.
In vitro morphine transport into the dialysis probe was measured by placing a dialysis probe in ascending concentrations of morphine sulfate, dissolved into dialysis buffer, using a flow rate of 2.13 jd/min and at room temperature. Morphine concentration was determined using the same HPLC-EC system used to detect dopamine except that the preoxidation electrode was set at +0.02 V and the working electrode was set at +0.35 V.
Determination of extracellular GABA. Samples for the GABA assay were collected into 10 ~1 of 5.0 PM 5-aminovaleric acid (AVA) in 0.1 M HCl. The concentration of GABA was determined using HPLC-EC AVA were used to quantify the concentration of GABA.
Histology and statistics. Upon completion of dialysis experiments, rats were killed by an overdose of sodium pentobarbital and phosphatebuffered saline was perfused transcardially followed by 10% formalin. The brain was removed and stored in formalin for at least 1 week. Coronal sections through the extent of the cannula tracks were cut (100 Frn) with a vibratome and then mounted on gelatin-coated slides and stained with cresyl violet. The location of the dialysis probe tracks was determined by an observer unaware of the animal's neurochemical response. In some rats, immunocytochemistry for tyrosine hydroxylase was performed as described elsewhere (Kalivas and Dully, 199 1) .
Neurochemical and behavioral (behavioral data were only available following the administration of muscimol) dose-response data were transformed into data points that represented the average of the last two 20 min dialysis (or behavioral) samples for each dose, and then analyzed by a one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparisons. Other neurochemical data were analyzed by a two-way, repeated-measures analysis of variance followed by the least-significant difference test for multiple comparisons (Milliken and Johnson, 1984) . The neurochemical data were converted to the percentage change from the average of three baseline measurements and are represented as such in the figures. Basal dopamine levels in the VTA (mean + SEM), not corrected for probe recovery, were calculated from the three predrug baseline values and are expressed as fmol/20 min.
Results

Morphine regulation of extracellular dopamine
A dose-response curve for the effect of morphine on extracellular dopamine content in the VTA is illustrated in Figure 1A . The administration of the higher concentrations of morphine (100 and 1000 PM) through the dialysis probe elicited a significant increase in the extracellular levels of dopamine in the VTA (Fig. 1B) . The levels were increased by approximately 250% following 100 PM, and 600% in response to 1000 I.LM morphine. Figure 2 shows the effect of morphine, naloxone, and a combination of both on extracellular dopamine in the VTA. Following a 20 min pulse of morphine (100 PM), the levels of dopamine gradually increased. The maximal effect was an approximate 175% increase above baseline values that occurred 40-60 min after the pulse and gradually returned to baseline levels 120 min after the pulse. The morphine-induced increase in dopamine was significantly attenuated by pretreatment with naloxone (2.0 mg/kg, i.p.), which by itself did not alter the extracellular concentration of dopamine.
Morphine regulation of extracellular GABA The effect of morphine administration on the concentration of extracellular GABA in the VTA is shown in Figure 3 . Application of morphine (100 FM) into the VTA through the dialysis probe produced a maximum 68% reduction in GABA levels during the 80 min administration period. The levels of GABA gradually returned to predrug values following the removal of morphine from the dialysis buffer. In contrast, levels of extracellular GABA were not significantly altered following the syringe switch containing only dialysis buffer.
Regulation of extracellular dopamine by baclofen Figure 4A shows a dose-response curve for the effect of baclofen on extracellular dopamine levels in the VTA. In contrast to the effects of morphine, baclofen decreased the extracellular do- alyzed with a one-way ANOVA followed by Dunnett's multiple comparisons. The F score for dose was F(4,32) = 5.37, p = 0.002. *, p < 0.05, using a Dunnett's test for comparison to predrug baseline. The number of subjects for each dose is indicated in the bar graph (I?). Basal dopamine levels in the VTA were 64 + 8 fmoV20 min.
pamine content in the VTA. Following the two highest doses of baclofen (100 and 1000 PM), dopamine concentrations in the VTA were reduced to approximately 40% and 25% of baseline levels, respectively (Fig. 4B ). Figure 5 shows the effect of a 20 min pulse of either morphine (100 KM), baclofen (100 PM), or an equimolar mixture on extracellular dopamine levels in the VTA. The morphine pulse elicited a significant increase in dopamine release, approximately 175% above baseline levels. Following a 20 min pulse of baclofen, the levels of dopamine dropped to 50% of baseline values for the remainder of the experiment (120 min). A similar reduction in the level of extracellular dopamine was produced following a 20 min pulse of an equimolar mixture of morphine and baclofen, which decreased dopamine levels to approximately 60% of the predrug baseline.
Effect of muscimol on extracellular dopamine A dose-response curve of the effect of muscimol on dopamine levels in the VTA is shown in Figure 6A . Application of mus- cimol through the dialysis probe into the VTA elicited a significant increase in the extracellular levels of dopamine. An approximate 200% increase in dopamine levels was produced following the administration of 10 and 100 PM muscimol (Fig.  6B ), but when the concentration was increased to 1000 PM, the levels of extracellular dopamine returned to baseline values. A pronounced increase in motor activity, in the form of contralateral rotation, was elicited following the three highest doses 
Dose (PM)
A, Dose-response curve for the effects of baclofen administration on extracellular dopamine levels in the VTA. Baclofen (l-l 000 FM) was applied in ascending concentrations through the dialysis probe. B, The transformed data (see Materials and Methods) were analyzed with a one-way ANOVA followed by Dunnett's multiple comparisons. N = 10-24 for each dose as indicated on the bar graph (B). The F score for dose was F(4,24) = 14.68, p = 0.0001. *, p < 0.05 compared to predrug baseline. Basal levels of dopamine were 7 1 + 15 fmoV20 min.
(10, 100, and 1000 MM) of muscimol tested (Fig. 60 . The maximal effect on motor activity was seen at the 100 PM dose (Fig.  60) and was characterized by tight, head-to-tail circling. Following the higher doses of muscimol, an apparent dissociation of the neurochemistry from the behavioral response is evident as motor activity remained elevated even as extracellular levels of dopamine declined. The uniphasic behavioral response may be attributable to a nonspecific action produced by muscimol at the higher doses. Figure 7 shows the effects of (1) *, p < 0.05 compared to morphine + baclofen using a least significant difference test (Milliken and Johnson, 1984) . Basal levels of dopamine in the VTA were MOR, 41 k 11 fmol/20 mitt; BAC, 38 k 5 fmolL20 min; and MOR+BAC, 42 + 11 fmol/20 min.
Control treatments and histology
effects on the levels of dopamine following either the syringe switch or the systemic saline injection. Figure 8 shows the in vitro recovery of morphine through the dialysis probe. The probe was placed in dialysis buffer containing various concentrations of morphine (0.1-100 KM), and a 20 min sample was collected. The relative percentage recovery in vitro at room temperature ranged from approximately 3% at 0.1 PM to 5.6% at 100 PM morphine. The low transport of morphine across the dialysis membrane may account for the relatively slow onset of the morphine-induced effects on extracellular dopamine and the necessity of using a concentration of 100 PM to produce an effect (see Figs. lA, 2) .
A photomicrograph of a typical bilateral placement terminating in the nucleus paranigralis of the VTA is shown in Figure  9A . This section, stained with cresyl violet, is at a level showing the maximal extent of the damage produced by the cannula tracks. Neurons in the ventral mesencephalon immunohistochemically stained for tyrosine hydroxylase are shown in Figure  9B . The area outlined in white, adjacent to the cannula track, is shown in Figure 9C . Note the presence of what appear to be healthy neurons immunohistochemically stained for tyrosine hydroxylase, some with a visible nucleus, in the vicinity of the glial scar produced by the track of the dialysis probe.
Discussion
The results of the present experiments demonstrate that the administration of morphine through a dialysis probe into the VTA elicits an increase in the levels of extracellular dopamine and a reduction in levels of GABA. The morphine-induced increase in dopamine was reversed by peripheral naloxone pretreatment, arguing that morphine acts on opioid receptors to promote somatodendritic dopamine release. This conclusion is in agreement with behavioral (Broekkamp et al., 1979 ; Kelley Joyce et al., 198 1; Kalivas et al., 1983; CalencoChoukroun et al., 1991) and neurochemical (Latimer et al., 1987; Cador et al., 1989; evidence suggesting that dopamine neurons in the VTA are activated by p-opioids. Although morphine stimulates dopamine neuronal activity and somatodendritic dopamine release, this effect has been proposed to occur via disinhibition. The stimulation of dopamine neurons in the VTA by iontophoretic morphine is not reversed by naloxone, while the inhibition of nondopamine cells is naloxone reversible (Gysling and Wang, 1983) . Other studies have also shown that nondopamine cells are inhibited by local application of morphine (Hommer and Pert, 1983; Matthews and German, 1984) . Lacey et al. (1989) used tissue slices from the rat substantia nigra to demonstrate that nondopamine neurons are hyperpolarized, while dopamine neurons are unaffected by the p-opioid agonist Tyr-D-Ala-Gly-MePhe-Gly(o1) (DAMGO). More recently, a similar observation was made in tissue slices from the rat VTA, where p-opioid agonists inhibited only nondopaminergic cells (Johnson and North, 1992a) . Furthermore, this effect was produced by M-and not by d-opioid agonists. The lack of a direct effect of morphine on dopamine cells identified in these electrophysiological studies has been corroborated using receptor autoradiography for the p-opioid ligand i2SI-DAMG0. Although destruction of dopamine neurons with 6-hydroxydopamine (6-OHDA) did not alter lz51-DAMGO binding in the VTA, quinolinic acid lesions resulted in a significant reduction (Dilts and Kalivas, 1989 ). Likewise, 6-OHDA lesions of the VTA did not alter the binding density of the 6-opioid ligand 1251-[D-penicillamine*~5]-enkephalin (Dilts and Kalivas, 1990) .
In apparent contrast to the localization of p-and &receptors to nondopaminergic elements within the VTA, electron micrographs of the VTA that were double labeled for enkephalin and tyrosine hydroxylase immunoreactivity revealed that many enkephalin-containing boutons abut tyrosine hydroxylase<on-taining perikarya (Sesack and Pickel, 1990 Time (min) Figure 7 . Extracellular levels of dopamine in the VTA following a change of syringes, both containing dialysis buffer alone, and after an injection of saline (1 .O ml/kg, i.p.), both indicated by arrows. The data were analyzed with a one-way repeated-measures ANOVA. N = 9. The F score for subjects was F(8,144) = 1.16, NS; time F(16,128) = 0.48, NS. Basal dopamine levels were 38 + 6 fmol/20 min.
detailed analysis of the morphology has demonstrated that densecore vesicles containing enkephalin immunoreactivity were generally not localized at points of synaptic contact on dopamine cells, suggesting a nonsynaptic release (Sesack and Pickel, 1992) . This anatomical observation, together with both electrophysiological findings demonstrating a lack of effect by opioids on dopamine cell membrane potential (Lacey et al., 1989; Johnson and North, 1992a) , and autoradiographic evidence showing an apparent lack of p-or h-receptors on dopamine cells Kalivas, 1989, 1990) , indicates that released enkephalin may have a paracrine-like function and diffuses into the extracellular space to act on nondopaminergic neurons and axon terminals adjacent to dopamine neurons in the VTA. Although the source of enkephalin terminals in the VTA is not well defined, there exist almost no enkephalin-immunoreactive neurons intrinsic to the VTA (Johnson et al., 1980; Khachaturian et al., 1983) and we recently observed that approximately 8% of the neurons in the nucleus accumbens and ventral pallidum retrogradely labeled by fluorogold iontophoresis into the VTA contained preproenkephalin mRNA (M. A. Klitenick and P. W. Kalivas, unpublished observations). The observation that morphine significantly reduced the concentration of extracellular GABA argues that at least a portion of the opioid receptors are on GABAergic neurons and/or presynaptic terminals in the VTA. Many of the nondopaminergic neurons in the VTA are thought to be GABAergic, have been shown to contain GABA, the GABA synthetic enzyme glutamic acid decarboxylase (GAD), as well as GAD mRNA (Fonnum et al., 1978; Ribak et al., 1980; Nagai et al., 1983; Ottersen and Storm-Mathisen, 1984; Sequier et al., 1988; Zhang et al., 199 l) , and may innervate dopaminergic cells within the VTA (Nagai et al., 1983; Ottersen and Storm-Mathisen, 1984) . Also, descending projections from the nucleus accumbens and ventral pallidum are thought to be GABAergic, and provide inhibitory release (Fonnum et al., 1978; Yim and Mogenson, 1980; Grace and Bunney, 1985; Haber et al., 1985) . The presence of both GABA receptor subtypes has been demonstrated within the ventral mesencephalon (Bowery et al., 1987; Churchill et al., 1992) , and it is clear from intracellular recording of dopamine neurons in tissue slices that both GABA, and GABA, receptors are located on dopamine neurons (Lacey et al., 1988; Johnson and North, 1992b) . While GABA, receptor stimulation elicits a late onset, long-duration hyperpolarization mediated by increased potassium conductance, stimulation of GABA, receptors produces a short-lived hyperpolarization mediated by increased chloride flux (Lacey et al., 1988; Seabrook et al., 1990; Johnson and North, 1992b) . Recent studies by North and coworkers indicate that the synaptic inputs to the GABA, and GABA, receptors on dopamine neurons are anatomically distinct, and originate from local interneurons and projections into the VTA, respectively (Johnson and North, 1992b; Sugita et al., 1992) . Furthermore, both the spontaneous and electrically stimulated GABA-dependent hyperpolarizations were inhibited by DAMGO (Johnson and North, 1992a) . In contrast to the findings of Sugita et al. (1992) and Johnson and North (1992a) , Yim and Mogenson (1980) showed that the hyperpolarizations produced by in vivo electrical stimulation of the nucleus accumbens were blocked by the indirect GABA, antagonist picrotoxin. The hyperpolarization of dopamine cells by stimulating GA-BA, receptors is consistent with the present observation that baclofen decreases extracellular dopamine content in the VTA. Furthermore, it is consistent with in vivo electrophysiological and behavioral studies showing that baclofen inhibits impulse generation in dopamine cells (Olpe et al., 1977; Grace and Bunney, 1980 ) and decreases the locomotor activity (Tanner, 1979; . However, the fact that the GABA, agonist muscimol increased somatodendritic dopamine release is inconsistent with the observation that the stimulation of GABA, receptors on dopamine neurons elicits membrane hyperpolarization. This inconsistency may result from a difference in the basal activity of the GABAergic afferents to dopamine neurons in vivo, as compared to in vitro tissue slices. Earlier in vivo electrophysiological experiments revealed that systemic musteedback onto dopamine cells in response to axonal dopamine cimol inhibits nondopamine cells, while simultaneously stim- ulating dopamine neurons in the ventral mesencephalon (MacNeil et al., 1978; Walters and Lakoski, 1978; Grace and Bunney, 1979; Waszczack and Walters, 1980) . Furthermore, iontophoretic GABA was found to be approximately 20 times more potent at inhibiting nondopamine cells compared to dopamine neurons (Grace and Bunney, 1979) . Likewise, low levels of electrical stimulation of striatonigral GABAergic feedback preferentially inhibited the firing frequency of nondopamine versus dopamine cells (Grace and Bunney, 1985) . The differential sensitivity of dopamine and nondopamine cells to GABA, agonists may explain the biphasic dose-response curve for muscimol-induced elevation in extracellular dopamine. Thus, the lower concentrations of muscimol would preferentially inhibit nondopamine cells, thereby indirectly stimulating dopamine neurons. The disinhibition of dopamine cells by GABA, agonists is further supported by the fact that the microinjection of muscimol into the VTA elicits motor stimulation that is associated with an increase in dopamine transmission in axon terminals (Wirtshafter and Klitenick, 1989; . Also, muscimol induced an efflux of dopamine from the VTA in tissue slices (Beart and McDonald, 1980) . Based upon these data, it is possible that the predominant in vivo tone preferentially stimulates GABA, receptors on nondopamine cells. The observation that 6-OHDA lesions did not lower the density of 3H-muscimol binding indicates that GABA, receptors are more densely localized on nondopaminergic elements in the VTA (Churchill et al., 1992) .
Furthermore, the microinjection of the indirect GABA, antagonist picrotoxin into the substantia nigra promoted the release of preloaded 3H-GABA, indicating tonic stimulation of GABA, receptors on GABAergic neurons (Kondo and Iwatsubo, 1978 ). This conclusion is also supported by some studies showing that the application of muscimol in vitro inhibits the release of radiolabeled GABA from substantia nigra tissue slices (Kondo and Iwatsubo, 1978; FYoran et al., 1988) . However, in one study using synaptosomes prepared from the substantia nigra, no evidence was obtained for the modulation of GABA release by GABA, receptor stimulation (Giralt et al., 1990) . Figure 10 shows a model that illustrates how opioids and GABA may modulate dopamine cells in the VTA. (It should be noted, however, that glial cells, which may also be involved in the regulation of transmitter levels in the VTA, have not been included in the present model.) The dopamine cell is innervated by GABA-containing terminals from two sources, a GABAergic interneuron and a descending input from the nucleus accumbens or ventral pallidum (Waalas and Fonnum, 1980; Ottersen and Storm-Mathisen, 1984) . The innervation from the descending input is to GABA, receptors, while the interneuron stimulates GABA, receptors (Johnson and North, 1992b; Sugita et al., 1992) . In addition, GABA, receptors on the GABA interneuron are innervated by descending GABAergic projections from the nucleus accumbens or ventral pallidum (Grace and Bunney, 1985; Johnson and North, 1992b; Churchill et al., 1992) . p-Opioid receptors are located presynaptically on descending GABAergic axon terminals innervating dopamine cells, as well as on the GABAergic interneuron (Dilts and Kalivas, 1989; Johnson and North, 1992a) . Given this arrangement of receptors and synaptic connections, the administration of a GABA, agonist would hyperpolarize dopamine cells and decrease somatodendritic dopamine release. In contrast, both GABA, and p-opioid agonists would increase somatodendritic dopamine release by inhibiting tonic GABAergic input to the dopamine cell.
